Recordati announces two appointments

17 October 2023

Italian drugmaker Recordati (REC: MI) has appointed Milan Zdravkovic as its executive vice president of Research & Development (R&D). The news confirms Recordati's continued commitment to affordable innovation, the company said.

Mr Zdravkovic, a Danish national, brings a wealth of experience to his new role, with an impressive track record in developing innovative compounds and leading R&D organizations within the pharmaceutical industry. His expertise spans a wide range of therapeutic areas, including diabetes, obesity, immunology, hematology, and infectious diseases, and with experience from both rare and non-rare diseases.

He has 25 years of life-science experience and has worked at pharma and biotech companies like Novo Nordisk (NOV: NO, Swedish Orphan Biovitrum(STO: SOBI) and SNIPR Biome, holding increasingly senior roles including head of R&D and chief medical officer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK